COMMUNIQUÉS West-GlobeNewswire

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
13/04/2026
The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis. 1 This minimally invasive blood test enables greater patient [...]
Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants
13/04/2026
Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants L'approbation dans l'urticaire chronique spontanée (UCS) pour les enfants [...]
SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT)
13/04/2026
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically meaningful improvements in [...]
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
13/04/2026
NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine Nxera to receive US [...]
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
11/04/2026
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent endometrial cancer [...]
NeuroSalt Under Investigation: What the 2026 Formulation Transparency Review Reveals About Botanical Ingredients, Dosage Disclosure, and Consumer Verification
11/04/2026
A detailed overview of NeuroSalt's five-ingredient plant-based nerve health supplement — covering botanical formula composition, ingredient-level research, dosage disclosure, 60-day refund policy, and the consumer [...]
Gentle Patches Claims Evaluated: 2026 Consumer Interest Rises Around Transdermal Wellness Patch Ingredients, Product Lineup, and Policy Transparency
11/04/2026
A timely 2026 release highlighting growing consumer research interest in skin-absorption wellness formats, ingredient themes, product variety, and publicly visible brand information across the Gentle Patches pill-free [...]
Glo & Spa-rkle Aesthetics and Medical Spa Unveils New State-of-the-Art Location in Lubbock, Texas
11/04/2026
Join the Grand Opening Celebration on May 1, 2026, for an Evening of Beauty and Innovation Lubbock, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Glo & Spa-rkle Aesthetics and Medical Spa , a leader in aesthetic and [...]
Best Medical Alert Systems 2026: Bay Alarm Medical Awarded Best Medical Alert System
10/04/2026
Bay Alarm Medical Recognized for Excellence in Safety and Innovation by Medical Daily Concord, CALIFORNIA, April 10, 2026 (GLOBE NEWSWIRE) -- Bay Alarm Medical, a leader in personal emergency response systems, has been [...]
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
10/04/2026
WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the [...]
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
10/04/2026
SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for [...]
Pelthos Therapeutics Announces CFO Transition
10/04/2026
Senior Vice President, Finance & Accounting John M. Gay named Chief Financial Officer DURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company [...]
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/04/2026
CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/04/2026
BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera [...]
Checkerspot Introduces Algolein™, a New Line of Specialized Lipids from Microalgae for Personal Care and Cosmetics
10/04/2026
Algolein™ debuts with a high-oleic algal oil under the name Algolein™ TG C18/80 designed without genetic modification using microalgae fermentation to deliver targeted performance, consistency, and sustainability [...]
IRADIMED CORPORATION to Participate at the 25th Annual Needham Virtual Healthcare Conference
10/04/2026
ORLANDO, Fla., April 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 25th Annual Needham Virtual Healthcare Conference. Iradimed’s CFO, Jack Glenn, will [...]
IVY Rx Claims Evaluated: 2026 Compounded GLP-1 Telehealth Program Details, Monthly Pricing Structure, Clinician Access Model, and Patient Eligibility Information
11/04/2026
New 2026 program information covers self-pay pricing tiers, HSA/FSA eligibility, compounded semaglutide and tirzepatide access, three-entity telehealth structure, and key considerations for prospective patients [...]
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
10/04/2026
WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
10/04/2026
Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children are living with DMD in the U.S. NEW YORK, April 10, 2026 (GLOBE NEWSWIRE [...]

Pages